281 related articles for article (PubMed ID: 19424036)
1. The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study.
Ekberg H; Mamelok RD; Pearson TC; Vincenti F; Tedesco-Silva H; Daloze P
Transplantation; 2009 May; 87(9):1360-6. PubMed ID: 19424036
[TBL] [Abstract][Full Text] [Related]
2. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
3. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients.
Chan L; Hartmann E; Cibrik D; Cooper M; Shaw LM
Transplantation; 2010 Jul; 90(1):31-7. PubMed ID: 20517177
[TBL] [Abstract][Full Text] [Related]
4. Conversion to low-dose tacrolimus or rapamycin 3 months after kidney transplantation: a prospective, protocol biopsy-guided study.
Pankewycz O; Leca N; Kohli R; Weber-Shrikant E; Said M; Alnimri M; Feng L; Patel S; Laftavi MR
Transplant Proc; 2011 Mar; 43(2):519-23. PubMed ID: 21440749
[TBL] [Abstract][Full Text] [Related]
5. Two doses of daclizumab with delayed introduction of low-dose tacrolimus in elderly recipients of cadaveric renal transplants from donors >55 years of age.
Osuna A; Gentil MA; Capdevila L; Cantarell C; Mazuecos A; Pereira P; Rodríguez-Algarra G; González-Molina M;
Transplant Proc; 2005 Apr; 37(3):1438-40. PubMed ID: 15866630
[TBL] [Abstract][Full Text] [Related]
6. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients.
van Hooff JP; Squifflet JP; Wlodarczyk Z; Vanrenterghem Y; Paczek L
Transplantation; 2003 Jun; 75(12):1934-9. PubMed ID: 12829890
[TBL] [Abstract][Full Text] [Related]
7. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus.
McAlister VC; Peltekian KM; Malatjalian DA; Colohan S; MacDonald S; Bitter-Suermann H; MacDonald AS
Liver Transpl; 2001 Aug; 7(8):701-8. PubMed ID: 11510015
[TBL] [Abstract][Full Text] [Related]
8. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats.
Lloberas N; Torras J; Alperovich G; Cruzado JM; Giménez-Bonafé P; Herrero-Fresneda I; Franquesa Ml; Rama I; Grinyó JM
Nephrol Dial Transplant; 2008 Oct; 23(10):3111-9. PubMed ID: 18469305
[TBL] [Abstract][Full Text] [Related]
9. Abbreviated AUC monitoring of cyclosporine more adequately identified patients at risk for acute rejection during induction of immunosuppressive therapy after kidney transplantation than recommended C2 concentration values.
Troncoso P; Ortiz AM; Jara A; Vilches S
Transplant Proc; 2009; 41(1):127-30. PubMed ID: 19249495
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study.
Ekberg H; Bernasconi C; Nöldeke J; Yussim A; Mjörnstedt L; Erken U; Ketteler M; Navrátil P
Nephrol Dial Transplant; 2010 Jun; 25(6):2004-10. PubMed ID: 20106825
[TBL] [Abstract][Full Text] [Related]
11. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results.
Bolin P; Shihab FS; Mulloy L; Henning AK; Gao J; Bartucci M; Holman J; First MR;
Transplantation; 2008 Jul; 86(1):88-95. PubMed ID: 18622283
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic variability of sirolimus in Taiwanese renal transplant recipients.
Chueh SC; Wang SM; Lai MK; Chen J
Transplant Proc; 2004 Sep; 36(7):2058-9. PubMed ID: 15518745
[TBL] [Abstract][Full Text] [Related]
13. Addition of sirolimus to cyclosporine in long-term kidney transplant recipients to withdraw steroid.
Citterio F; Sparacino V; Altieri P; Rigotti P; Calabrese S; Poli M; Vinti V; Segoloni GP
Transplant Proc; 2005 Mar; 37(2):827-9. PubMed ID: 15848545
[TBL] [Abstract][Full Text] [Related]
14. Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin.
Lehmkuhl H; Hetzer R
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S201-5; discussion S210-1. PubMed ID: 15774323
[TBL] [Abstract][Full Text] [Related]
15. Everolimus in clinical practice--renal transplantation.
Pascual J
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
[TBL] [Abstract][Full Text] [Related]
16. Different effect of cyclosporine and tacrolimus on renal expression of P-glycoprotein in human kidney transplantation.
Yu X; Zhang B; Xing C; Sun B; Liu M; Zhang W; Gu M
Transplant Proc; 2008 Dec; 40(10):3455-9. PubMed ID: 19100412
[TBL] [Abstract][Full Text] [Related]
17. No-load sirolimus with tacrolimus and steroids is safe and effective in renal transplantation.
Tellis V; Schechner R; Mallis M; Rosegreen S; Glicklich D; Moore N; Greenstein S
Transplant Proc; 2005 Mar; 37(2):906-8. PubMed ID: 15848571
[TBL] [Abstract][Full Text] [Related]
18. Everolimus with reduced-dose cyclosporine in de novo renal transplant recipients: Philippine experience.
Li JT; Danguilan RA; Cabanayan-Casasola CB; Talusan-Tomacruz Y; Ona ET
Transplant Proc; 2008 Sep; 40(7):2211-3. PubMed ID: 18790195
[TBL] [Abstract][Full Text] [Related]
19. Stable graft function after reduction of calcineurin inhibitor dosage in paediatric kidney transplant patients.
Plank C; Benz K; Amann K; Nüsken KD; Dittrich K; Rascher W; Sauerstein K; Stuppy A; Klare B; Dötsch J
Nephrol Dial Transplant; 2006 Oct; 21(10):2930-7. PubMed ID: 16837512
[TBL] [Abstract][Full Text] [Related]
20. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?
Nashan B
Transplant Rev (Orlando); 2009 Jan; 23(1):47-52. PubMed ID: 19027616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
